Lv3
394 积分 2023-07-18 加入
Datopotamab dearuxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Ann Oncol. 2026 Aug;37(8):1066-1080
1个月前
已完结
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead
1个月前
已完结
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
2个月前
已完结
88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis
3个月前
已关闭
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
3个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
3个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
3个月前
已完结
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)
3个月前
已关闭
从循证到精准，推动睡眠呼吸暂停诊疗新范式
6个月前
已完结
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis
6个月前
已完结
皖公网安备34019202002308
